Hu Chao, Liu Yinhua, Jiang Shan, Chen Hongjin, Xu Haojun, Hu Junhong, Li Congzhu, Xia Hongping
State Key Laboratory of Reproductive Medicine & Department of Pathology in the School of Basic Medical Sciences & The Affiliated Sir Run Run Hospital & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, China.
Department of Pathology, The First Affiliated Yijishan Hospital of Wannan Medical College & Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institutes, Wannan Medical College, Wuhu, China.
Clin Transl Med. 2020 Jun;10(2):e49. doi: 10.1002/ctm2.49. Epub 2020 Jun 14.
Estrogen receptor (ER) is essential in reproductive development and is also the primary driver of breast cancers. Deregulation of ER may also be involved in tumorigenesis of other organs. To understand the role of ER in different tumor types, pan-cancer analysis of estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2) in various tumors and association with patients' survival were conducted using The Cancer Genome Atlas (TCGA) data.
Gene methylation level was evaluated by the mean methylation level of CpG sites in the promoter region. The significant different DNA methylation between tumor and healthy tissues was shown in 10 tumor types for ESR1 and eight tumor types for ESR2. The methylation pattern was also varied across different TCGA tumors. The pan-cancer analysis showed significantly different mRNA expression of ESR1 in nine tumor types and ESR2 in four tumor types. Survival analysis showed that the effects of ERs expression on survival are diverse in different tumors. The expression of ERs was associated with tumor molecular subtypes and various clinical characteristics. ER correlated genes were mainly enriched in cancer and immune-related pathways.
Our pan-cancer analysis data indicated that ERs might be significantly associated with carcinogenesis and progression of some tumors, which may be potential therapeutic targets and prognosis biomarkers.
雌激素受体(ER)在生殖发育中至关重要,也是乳腺癌的主要驱动因素。ER的失调也可能参与其他器官的肿瘤发生。为了解ER在不同肿瘤类型中的作用,利用癌症基因组图谱(TCGA)数据对各种肿瘤中的雌激素受体α(ESR1)和雌激素受体β(ESR2)进行了泛癌分析,并分析了其与患者生存的相关性。
通过启动子区域CpG位点的平均甲基化水平评估基因甲基化水平。ESR1在10种肿瘤类型中以及ESR2在8种肿瘤类型中显示出肿瘤组织与健康组织之间存在显著不同的DNA甲基化。甲基化模式在不同的TCGA肿瘤中也有所不同。泛癌分析显示,ESR1在9种肿瘤类型中以及ESR2在4种肿瘤类型中存在显著不同的mRNA表达。生存分析表明,ERs表达对生存的影响在不同肿瘤中各不相同。ERs的表达与肿瘤分子亚型和各种临床特征相关。ER相关基因主要富集在癌症和免疫相关途径中。
我们的泛癌分析数据表明,ERs可能与某些肿瘤的发生和进展显著相关,可能是潜在的治疗靶点和预后生物标志物。